Biotechnology & Biosafety
AI–Bio Convergence — Governance Under a Capability Shift
Advances at the AI–biology interface outpace the oversight meant to govern them.
Duration
120 min
Injects
5
Audience
National biosecurity policy, research funders & regulators, AI governance, ethics
Situation
A step-change in AI tools relevant to the life sciences prompts national concern that existing biosecurity oversight — designed for a slower, more concentrated research landscape — no longer matches the risk or pace of the field. No incident has occurred. This exercise is deliberately anticipatory: it tests whether governance, screening and coordination can adapt before, rather than after, a capability shift is exploited. The focus throughout is policy, oversight and coordination — not technical detail.
Exercise objectives
- Stress-test whether existing biosecurity governance keeps pace with a fast-moving enabling technology.
- Exercise coordination across three communities that rarely share a table: biosecurity, AI governance and research funding.
- Examine practical safeguards — nucleic-acid synthesis screening, access controls, know-your-customer, publication norms — and who owns them.
- Rehearse a proportionate response that manages risk without foreclosing beneficial science.
Capability stress
How hard this scenario tests each of the 10 benchmark dimensions (1–5).
Foresight lens
Being able to cope with a threat that is precedent-free — a pathogen, dynamic or context we have NOT seen, where experience can actively mislead. Readiness is an adaptive capacity, not a plan for a known pattern.
TUNA profile
Assumptions this scenario windtunnelsfull register →
A2The next serious pathogen will resemble what we have seen (respiratory).
Sensitivity: high · TUNA: N
A6Existing biosecurity/biosafety oversight matches the pace of the science.
Sensitivity: high · TUNA: U · A · N
Scenario parameters
Illustrative planning figures for discussion — not operational data.
Trigger
Anticipated capability shift at the AI–bio interface (no incident)
Posture
Anticipatory governance, not incident response
Oversight maturity
Designed for a slower, more concentrated field
Safeguards in scope
Synthesis screening, access controls, publication norms
Stakeholders
Biosecurity, AI governance, funders, industry, academia
Time pressure
Policy cycles in years; technology in months
Roles at the table
National Biosecurity Policy Lead
Owns the biological-risk governance response.
AI Governance Lead
Owns oversight of the enabling technology.
Research Funder / Regulator
Owns the conditions attached to funding and approvals.
Synthesis-Industry Liaison
Represents providers implementing screening and access controls.
Ethics & Openness Adviser
Balances beneficial science, openness and misuse risk.
Inject timeline
- T+0Capability concern raised
An expert body warns that oversight may be lagging the field.
- T+2wScreening gap
A review finds nucleic-acid synthesis screening is voluntary and incomplete.
- T+4wJurisdiction gap
The fast-moving capability falls between biosecurity and AI mandates; neither clearly owns it.
- T+6wPublic attention
Media coverage frames it as a governance failure-in-waiting; pressure to act rises.
- T+8wProposal on the table
A draft safeguards package is proposed; industry and academia raise feasibility and openness concerns.
Decision points
D1Where should authority sit for a risk that straddles biosecurity and AI governance — and who convenes it?
- The cost of a risk that falls between two mandates and is owned by neither.
- Whether a standing coordination body exists or must be created.
- How to give one owner authority without stalling in inter-agency negotiation.
D2Which safeguards are proportionate now, given they impose real costs on legitimate science?
- Risk reduction per unit of burden on beneficial research.
- Which safeguards are voluntary today and could be made standard.
- Feasibility for small labs and academic groups, not just large industry.
D3How do you strengthen oversight without driving research to less-governed jurisdictions?
- The displacement risk of unilateral national controls.
- The value of international alignment and shared screening standards.
- Keeping the beneficial mainstream of the science open and productive.
Response playbook
Assess
- Map the governance gap
- Convene the three communities
- Inventory existing safeguards
- Define the risk in plain terms
Coordinate
- Assign clear ownership
- Align biosecurity and AI mandates
- Engage industry and academia early
- Agree decision rights
Safeguard
- Strengthen synthesis screening and access controls
- Update funding conditions
- Revisit publication and responsible-disclosure norms
- Support smaller labs to comply
Sustain
- Build an adaptive review cadence tied to capability signals
- Pursue international alignment
- Monitor for displacement effects
- Protect beneficial research
After-action questions
- Did any single body actually own this cross-cutting risk, or did it fall between mandates?
- Which safeguard gives the most risk reduction for the least burden on legitimate science?
- What signal would tell you oversight has fallen dangerously behind — and are you watching it?
National benchmark references
Real national strategies from the Global Pandemic Preparedness Benchmark that inform this scenario.